Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 397, Issue -, Pages 84-91Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2018.11.031
Keywords
Immunoglobulin; IVIg; Chronic inflammatory demyelinating polyneuropathy; Corticosteroid; Best practices; Survey
Categories
Funding
- Grifols (Research Triangle Park, NC), a manufacturer of IVIg
Ask authors/readers for more resources
To evaluate how neurologists make decisions regarding chronic inflammatory demyelinating polyneuropathy (CIDP), we conducted a cross-sectional quantitative survey of 100 community neurologists in the United States. Only 13% cited using the European Federation of Neurological Societies/Peripheral Nerve Society guideline. In addition, variability in treatment approaches existed regarding the dose of IVIg used, the length of IVIg therapy before determining response, the outcome measures used to determine IVIg response, and the protocol for weaning off therapy. Forty-three percent reported giving doses that were lower than the recommended IVIg loading dose for CIDP. Many reported giving nonspecific patient education about the rationale of IVIg use and treatment duration. The finding that approximately half of community neurologists endorsed electrodiagnostic criteria that do not support CIDP diagnosis indicated difficulties relying heavily upon neurophysiologic studies in diagnostic guidelines. More education on CIDP diagnosis and treatment and a clear, actionable, clinically focused guideline would enhance best practices, particularly in the midst of high information flow and multiple guidelines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available